Cetera Investment Advisers
CAPR icon

Cetera Investment Advisers’s Capricor Therapeutics CAPR Stock Holding History

Cetera Investment Advisers’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,342
Closed -$223K – 5036
2026
Q1 		$223K Buy
7,342
+149
+2% +$3.97K ﹤0.01% 4211
2025
Q4 		$208K Sell
7,193
-3,393
-32% -$44.3K ﹤0.01% 4208
2025
Q3 		$76.3K Buy
+10,586
New +$77.9K ﹤0.01% 4373

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cetera Investment Advisers's CAPR Position: Q2 2026 in Review

Cetera Investment Advisers sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 7,342 shares — an estimated $223K sold.

Cetera Investment Advisers first reported a position in CAPR in Q3 2025 and held it in 3 quarters. The position peaked at $223K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Cetera Investment Advisers reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 7,342 Capricor Therapeutics shares in Q2 2026, an estimated $223K.
  • Cetera Investment Advisers first reported a position in Capricor Therapeutics in Q3 2025 and held it in 3 quarters.
  • Cetera Investment Advisers's Capricor Therapeutics position peaked at $223K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.